MX2020009935A - Formulaciones acuosas y estables de anticuerpos anti-tau. - Google Patents

Formulaciones acuosas y estables de anticuerpos anti-tau.

Info

Publication number
MX2020009935A
MX2020009935A MX2020009935A MX2020009935A MX2020009935A MX 2020009935 A MX2020009935 A MX 2020009935A MX 2020009935 A MX2020009935 A MX 2020009935A MX 2020009935 A MX2020009935 A MX 2020009935A MX 2020009935 A MX2020009935 A MX 2020009935A
Authority
MX
Mexico
Prior art keywords
stable aqueous
tau antibody
antibody formulations
aqueous anti
stable
Prior art date
Application number
MX2020009935A
Other languages
English (en)
Inventor
Katharina Kaleta
Michael Siedler
Martin Hülsmeyer
Jonas Angstenberger
Kerstin Appenzeller
Tanja Meyer
Christian Ried
Christine Rinn
Kathrin Schäker-Theobald
Axel Wilbertz
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MX2020009935A publication Critical patent/MX2020009935A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona composiciones tamponadas, acuosas y estables que comprenden una alta concentración de ABBV-8E12, tal como una composición tamponada, acuosa y estable que incluye ABBV-8E12 a una concentración de aproximadamente 100 mg/ml, al menos un tampón, un excipiente, un tensioactivo y opcionalmente un antioxidante.
MX2020009935A 2018-03-23 2019-03-22 Formulaciones acuosas y estables de anticuerpos anti-tau. MX2020009935A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647615P 2018-03-23 2018-03-23
PCT/EP2019/057343 WO2019180261A1 (en) 2018-03-23 2019-03-22 Stable aqueous anti-tau antibody formulations

Publications (1)

Publication Number Publication Date
MX2020009935A true MX2020009935A (es) 2021-01-08

Family

ID=65991783

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009935A MX2020009935A (es) 2018-03-23 2019-03-22 Formulaciones acuosas y estables de anticuerpos anti-tau.

Country Status (12)

Country Link
US (1) US20210023216A1 (es)
EP (1) EP3768706A1 (es)
JP (1) JP2021519268A (es)
CN (1) CN112004827A (es)
AR (1) AR117407A1 (es)
AU (1) AU2019237252A1 (es)
BR (1) BR112020019065A2 (es)
CA (1) CA3094934A1 (es)
MX (1) MX2020009935A (es)
TW (1) TW202003036A (es)
UY (1) UY38153A (es)
WO (1) WO2019180261A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MX2011011772A (es) * 2009-05-04 2012-02-08 Abbott Biotech Ltd Formulaicones estables de anticuerpos humanos anti-tnf-alfa con alta concentracion de proteina.
AU2010320515B2 (en) * 2009-11-20 2013-05-02 Biocon Limited Formulations of antibody
HK1209768A1 (en) 2012-07-03 2016-04-08 Washington University Antibodies to tau
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
TWI738632B (zh) * 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
MA41451A (fr) * 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
WO2016201434A2 (en) 2015-06-12 2016-12-15 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions

Also Published As

Publication number Publication date
BR112020019065A2 (pt) 2020-12-29
EP3768706A1 (en) 2021-01-27
TW202003036A (zh) 2020-01-16
AR117407A1 (es) 2021-08-04
CA3094934A1 (en) 2019-09-26
US20210023216A1 (en) 2021-01-28
AU2019237252A1 (en) 2020-10-22
WO2019180261A1 (en) 2019-09-26
JP2021519268A (ja) 2021-08-10
CN112004827A (zh) 2020-11-27
UY38153A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
MX2020009935A (es) Formulaciones acuosas y estables de anticuerpos anti-tau.
EP4360651A3 (en) Glp-1 compositions and uses thereof
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
EP4385514A3 (en) Formulations
MX2020008219A (es) Formulacion farmaceutica de ph bajo.
WO2019147749A3 (en) Stabilized rsv f proteins and uses thereof
TN2018000443A1 (en) Stable liquid pharmaceutical preparation
EP4233843A3 (en) Antibody compositions
CL2020002252A1 (es) Formulación oftálmica.
EP4233892A3 (en) Stable anti-ifnar1 formulation
ZA202407615B (en) Formulations of dengue virus vaccine compositions
WO2019120234A3 (zh) 作为溴结构域蛋白质抑制剂的化合物和组合物
AU2019339740A8 (en) CSF-1R antibody formulation
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
ZA202107826B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
MX2023008333A (es) Nanomateriales.
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
MX2020008125A (es) Composiciones que comprenden berberina.
EA202192646A1 (ru) Лиофилизированная композиция, содержащая соединение бензоазепина
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
MX420767B (es) Proteina de union al factor h modificada
EP4606435A3 (en) Pharmaceutical composition comprising poorly soluble basic agent
MX2023014616A (es) Formulaciones de anticuerpos anti-pd1.
BR112022022620A2 (pt) Formulações de anticorpos anti-il-33
MX2022001805A (es) Formulaciones de anticuerpos anti-esclerostina.